Eli Lilly's Bullish Analyst Targets Clash With Foundayo's Disappointing Debut

The disconnect between Wall Street's enthusiasm and Eli Lilly's stock performance is widening by the day. While roughly 95% of analysts maintain buy ratings and the average price target sits at a lofty $1,225—implying a 38.5% upside from current levels—the shares themselves have been sliding. On Friday, the stock closed at €750 in Frankfurt, slipping below its 200-day moving average of €782 and marking a year-to-date decline of roughly 18%.

The immediate catalyst for the latest leg lower was a stark reality check for the company's newly launched oral weight-loss drug Foundayo. Approved by the FDA on April 1, the medication generated just 3,700 prescriptions in its second week on the market. That figure fell far short of the roughly 8,000 scripts analysts had hoped to see as evidence of sustainable commercial traction. The contrast with rival Novo Nordisk's oral Wegovy is particularly painful—the Danish competitor racked up more than 18,400 prescriptions in the same post-launch window.

Pipeline Promise Versus Market Reality

The Foundayo stumble comes at a particularly sensitive moment. Eli Lilly is set to report first-quarter results on April 30, and expectations are elevated following a strong close to 2025. The consensus calls for revenue of approximately $17.6 billion and earnings per share of $7.26. With the stock now trading more than 21% below its 52-week high, the earnings call will be a critical test of management's ability to reassure investors that Foundayo's slow start is merely a teething issue rather than a structural problem.

Despite the near-term headwinds, the company's core growth story remains intact. The established obesity treatments Mounjaro and Zepbound continue to drive revenue, while the pipeline features the promising experimental drug Retatrutide. Strategic acquisitions of Kelonia and a $10 billion investment in an AI drug-development partnership, along with a sleep-disorder pipeline purchase, underscore management's commitment to long-term expansion. The research budget for 2025 exceeded $13 billion.

Divergent Views on Valuation

Analyst sentiment is increasingly split. HSBC recently downgraded Eli Lilly to "Reduce" and slashed its price target to $850, while other firms maintain their bullish stances. The stock's forward price-to-earnings ratio of roughly 39 actually looks reasonable compared to the broader market's average of 44, a discount that some see as an attractive entry point given the projected earnings growth of 43% in fiscal 2026 and an additional 21% the following year.

Institutional investors, who control about three-quarters of the shares, are sending mixed signals. M&T Bank increased its position, while other funds trimmed their holdings. The upcoming earnings release will likely determine which camp gains the upper hand. If management can demonstrate that Foundayo's prescription trajectory is accelerating and that the broader pipeline remains on track, the ambitious Wall Street targets may come back into focus. For now, the stock finds itself caught between analyst optimism and market skepticism, with the next major catalyst just days away.

Ad

Eli Lilly Stock: New Analysis - 27 April

Fresh Eli Lilly information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Eli Lilly analysis...